Published peptide research references
Pramlintide
Governed registry record
184 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.
Open the peptide evidence profile →Approved source records
Correction to: Liraglutide versus pramlintide in protecting against cognitive function impairment through affecting PI3K/AKT/GSK‑3β/TTBK1 pathway and decreasing Tau hyperphosphorylation in high‑fat dietstreptozocin rat model.
DOI: 10.1007/s00424-024-02959-4PMID: 38575720
Source identity and connection checked by Codex (AI).
Development and validation of a new robust RP-HPLC method for simultaneous quantitation of insulin and pramlintide in non-invasive and smart glucose-responsive microparticles.
DOI: 10.4103/1735-5362.359428PMID: 36704426
Source identity and connection checked by Codex (AI).
Dextran Sulfate/Pramlintide Polyelectrolyte Nanoparticles as a Promising Delivery System: Optimization, Evaluation of Supramolecular Interactions and Effect on Conformational Stability of the Peptide Drug
DOI: 10.21577/0103-5053.20210062
Source identity and connection checked by Codex (AI).
Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Systematic Review
Source identity and connection checked by Codex (AI).
Effect of Zn(II) on pramlintide: structural kink, fibril formation, antifungal activity
DOI: 10.21203/rs.3.rs-1954176/v1
Source identity and connection checked by Codex (AI).
Injectable Biodegradable Silica Depot: Two Months of Sustained Release of the Blood Glucose Lowering Peptide, Pramlintide.
DOI: 10.3390/pharmaceutics14030553PMID: 35335929
Source identity and connection checked by Codex (AI).
Intranasal administration of dextran-pramlintide polyelectrolyte complex-coated nanoemulsions improves cognitive impairments in a mouse model of Alzheimer's disease.
DOI: 10.1016/j.ijbiomac.2024.136158PMID: 39362444
Source identity and connection checked by Codex (AI).
Oral delivery of the amylin receptor agonist pramlintide
DOI: 10.1101/2023.11.09.566408
Source identity and connection checked by Codex (AI).
Polysaccharide-peptide complexes stabilized around nanoemulsion droplets: A new approach for nasal delivering of pramlintide and insulin
DOI: 10.1016/j.jddst.2023.104527
Source identity and connection checked by Codex (AI).
QBD Approach for Design and Characterization of Pramlintide Microspheres for Controlled Drug Release
DOI: 10.1007/s12247-023-09795-6
Source identity and connection checked by Codex (AI).
Slow post-induction specific growth rate enhances recombinant protein expression in Escherichia coli: Pramlintide multimer and ranibizumab production as case studies
DOI: 10.1016/j.procbio.2022.01.009
Source identity and connection checked by Codex (AI).
Ultra-fast insulin-pramlintide co-formulation for improved glucose management in diabetic rats
DOI: 10.1101/2021.04.12.439573
Source identity and connection checked by Codex (AI).
A Pilot Outpatient Assessment of a Fully Closed-Loop Insulin and Pramlintide System.
2025
Central pramlintide administration potently suppresses operant responding for sucrose and locomotor activity in male rats.
2025
In silico evaluation of pramlintide dosing algorithms in artificial pancreas systems.
2025
Intranasal pramlintide matches intraperitoneal effects on food intake and gastric emptying in mice.
2025
A model of subcutaneous pramlintide pharmacokinetics and its effect on gastric emptying: Proof-of-concept based on populational data.
2024
A temperature-responsive dual-hormone foam nanoengine improves rectal absorptivity of insulin-pramlintide for diabetes treatment.
2024
ADO09, a co-formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes.
2024
Chronic pramlintide decreases feeding via a reduction in meal size in male rats.
2024
Liraglutide versus pramlintide in protecting against cognitive function impairment through affecting PI3K/AKT/GSK-3β/TTBK1 pathway and decreasing Tau hyperphosphorylation in high-fat diet- streptozocin rat model.
2024
Pramlintide an Adjunct to Insulin Therapy: Challenges and Recent Progress in Delivery.
2024
Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada.
2024
A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes.
2023
Contraction of human brain vascular pericytes in response to islet amyloid polypeptide is reversed by pramlintide.
2023
Pramlintide for post-bariatric hypoglycaemia.
2022
Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming.
2022
Pramlintide: An Amylin Analogue Protects Endothelial Cells against Oxidative Stress through Regulating Oxidative Markers and NF-κb Expression.
2022
Zn(II) binding to pramlintide results in a structural kink, fibril formation and antifungal activity.
2022
ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes.
2021
Alleviating carbohydrate counting with a FiASP-plus-pramlintide closed-loop delivery system (artificial pancreas): Feasibility and pilot studies.
2021
Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients.
2021
Effects of pramlintide on energy intake and food preference in rats given a choice diet.
2021
Ultra-Fast Insulin-Pramlintide Co-Formulation for Improved Glucose Management in Diabetic Rats.
2021
A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial.
2020
A co-formulation of supramolecularly stabilized insulin and pramlintide enhances mealtime glucagon suppression in diabetic pigs.
2020
Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts.
2020
Rediscovery of the Second β-Cell Hormone: Co-replacement With Pramlintide and Insulin in Type 1 Diabetes.
2020
The effect of pramlintide, an antidiabetic amylin analogue, on angiogenesis-related markers <i>in vitro</i>.
2020
Neuroprotective Effects of the Amylin Analog, Pramlintide, on Alzheimer's Disease Are Associated with Oxidative Stress Regulation Mechanisms.
2019
Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.
2018
Physico-chemical properties of co-formulated fast-acting insulin with pramlintide.
2018
Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes.
2018
Pramlintide regulation of extracellular matrix (ECM) and apoptosis through mitochondrial-dependent pathways in human nucleus pulposus cells.
2018
Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy.
2018
Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease.
2018
Study of forced degradation behavior of pramlintide acetate by HPLC and LC-MS.
2018
Be positive: optimizing pramlintide from microcanonical analysis of amylin isoforms.
2017
Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis.
2017
Pramlintide Antagonizes Beta Amyloid (Aβ)- and Human Amylin-Induced Depression of Hippocampal Long-Term Potentiation.
2017
Zn(II) - pramlintide: Stability, binding sites and unexpected aggregation.
2017
Amyloidogenesis of the amylin analogue pramlintide.
2016
Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes.
2016
Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials.
2016
Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide.
2016
Synthesis and amylin receptor activity of glycomimetics of pramlintide using click chemistry.
2016
Analysis of the ability of pramlintide to inhibit amyloid formation by human islet amyloid polypeptide reveals a balance between optimal recognition and reduced amyloidogenicity.
2015
Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes.
2015
A model of glucose-insulin-pramlintide pharmacokinetics and pharmacodynamics in type I diabetes.
2014
Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.
2014
Convergent chemoenzymatic synthesis of a library of glycosylated analogues of pramlintide: structure-activity relationships for amylin receptor agonism.
2014
Effects of pramlintide in patients with type 2 diabetes mellitus: an analysis using daily insulin dose tertiles.
2014
Expression, purification, and biological activity of the recombinant pramlintide precursor.
2014
Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition.
2014
Glycosylation of pramlintide: synthetic glycopeptides that display in vitro and in vivo activities as amylin receptor agonists.
2013
In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes.
2013
Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QR.
2013
Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy.
2013
Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol.
2013
Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes.
2013
Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes.
2012
Pramlintide
2012
Pramlintide: profile of an amylin analog.
2012
[D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.
2012
Pramlintide and the treatment of diabetes: a review of the data since its introduction.
2011
Primer on pramlintide, an amylin analog.
2011
The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis.
2011
Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patients.
2010
Dose accuracy and injection force of disposable pens delivering pramlintide for the treatment of diabetes.
2010
Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus.
2010
Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.
2010
Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs.
2010
Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: a large observational study.
2010
The role of pramlintide for weight loss.
2010
A pilot trial of pramlintide home usage in adolescents with type 1 diabetes.
2009
Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study.
2009
Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.
2009
Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is used.
2009
Pramlintide in pediatric type 1 diabetes.
2009
Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.
2009
Psychometric properties of an instrument for assessing treatment satisfaction associated with pramlintide use.
2009
Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.
2009
Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus.
2009
Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes.
2009
Solution state structures of human pancreatic amylin and pramlintide.
2009
A biophysical characterization of the peptide drug pramlintide (AC137) using empirical phase diagrams.
2008
Clinical experience with the addition of pramlintide in patients with insulin-requiring type 2 diabetes.
2008
Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy.
2008
Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes.
2008
Pramlintide in the treatment of diabetes mellitus.
2008
Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes.
2008
Pramlintide reduces the risks associated with glucose variability in type 1 diabetes.
2008
Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk.
2008
Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity.
2008
Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy.
2007
Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes.
2007
Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?
2007
Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects.
2007
Pharmacokinetics of an oral drug (acetaminophen) administered at various times relative to subcutaneous injection of pramlintide in subjects with type 2 diabetes.
2007
Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
2007
Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight.
2007
Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.
2007
Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study.
2007
Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study.
2007
The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
2007
Therapies for diabetes: pramlintide and exenatide.
2007
A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
2006
Adjunctive therapy with pramlintide in patients with type 1 or type 2 diabetes mellitus.
2006
Diabetes basics. Exenatide and pramlintide. New meds on the block.
2006
Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus.
2006
Exenatide and pramlintide: new therapies for diabetes.
2006
Pramlintide
2006
Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes.
2006
Pramlintide in the treatment of diabetes.
2006
Pramlintide: A new tool in diabetes management.
2006
Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide.
2006
Use of Pramlintide: The Patient's Perspective
2006
Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.
2005
Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes.
2005
Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes.
2005
New drugs: exenatide, pramlintide acetate, and micafungin sodium.
2005
Pramlintide (symlin) for diabetes.
2005
Pramlintide acetate.
2005
Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
2005
Properties of pramlintide and insulin upon mixing.
2005
The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes.
2005
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
2004
Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects.
2004
Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.
2004
Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data.
2004
Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
2004
Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets.
2003
Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis.
2003
Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4).
2003
Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
2003
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
2003
Pramlintide for the treatment of diabetes mellitus.
2003
Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
2003
Pramlintide: (AC 137, AC 0137, Symlin, Tripro-Amylin).
2003
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
2002
Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.
2002
Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1.
2002
Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus.
2002
Is pramlintide an adjunct to insulin therapy?
2002
Pramlintide: an agent for glycemic control plus weight control?
2002
The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
2002
The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
2002
Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control.
2001
Pramlintide (Amylin).
2001
Pramlintide: FDA wants more.
2001
Kinetics of pramlintide degradation in aqueous solution as a function of temperature and pH.
2000
Orthogonal HPLC methods for quantitating related substances and degradation products of pramlintide.
2000
Pramlintide injection drug product robustness studies.
2000
Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition.
2000
Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects.
1999
Isolation and identification of cyclic imide and deamidation products in heat stressed pramlintide injection drug product.
1999
Pramlintide. AC 137, ACO 137, Normylin, Symlin, Tripro-amylin.
1999
The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.
1999
The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus.
1999
USAN Council. List No. 419. New names. Pramlintide acetate.
1999
Isolation and identification of peptide degradation products of heat stressed pramlintide injection drug product.
1998
Nephrectomy decreases amylin and pramlintide clearance in rats.
1998
Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group.
1998
The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM.
1998
[Effects of pramlintide, an analog of amylin, on the regulation of glycemia].
1998
Amylin and glycaemic regulation: a possible role for the human amylin analogue pramlintide.
1997
DOI: 10.1002/(sici)1096-9136(199706)14:2+<s35::aid-dia402>3.3.co;2-#PMID: 9212328
Amylin's pramlintide best of bad bunch of diabetes drugs.
1997
Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations.
1997
Effects of Amylin and the Amylin Agonist Pramlintide on Glucose Metabolism
1997
DOI: 10.1002/(sici)1096-9136(199706)14:2+<s19::aid-dia400>3.0.co;2-4PMID: 9212325
Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial.
1997
Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM.
1997
Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes.
1997
DOI: 10.1002/(sici)1096-9136(199707)14:7<547::aid-dia390>3.0.co;2-uPMID: 9223392
USAN Council. List No.392. New names. Pramlintide.
1997
Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.
1996